Bristol-Myers Squibb (BMY) AI Stock Analysis

• Market Cap: $95.32B
• Dividend Yield: 6.28%
• Average Volume (3M): 13.58M
• Price to Earnings (P/E): 17.6
• Beta (1Y): 0.17
• Revenue Growth: 4.62%
• EPS Growth: N/A
• Country: US
• Employees: 34,100
• Sector: Healthcare
• Sector Strength: 48
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.80
• Shares Outstanding: 2,035,080,800
• 10 Day Avg. Volume: 11,677,818
• 30 Day Avg. Volume: 13,578,962
• PEG Ratio: -4.24
• Price to Book (P/B): 4.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.83
• Enterprise Value/Market Cap: 1.94
• Enterprise Value/Revenue: 0.97
• Enterprise Value/Gross Profit: 5.88
• Enterprise Value/Ebitda: 6.26
• 1Y Price Target: $59.53
• Price Target Upside: 27.09% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 20

• Rating: 63 Neutral
• Price Target: ―

Bristol-Myers Squibb's overall stock score reflects strong financial performance, particularly in cash flow generation and gross profitability. The recent earnings call provided positive revenue and EPS guidance, supporting a strong outlook. However, technical indicators show bearish momentum, and some regulatory and trial challenges persist. The balanced valuation and attractive dividend yield provide additional support.

Positive Factors

Business Development

Bristol Myers announced entry into a partnership with BioNTech to co-develop and co-commercialize BioNTech’s PD-L1xVEGF bispecific antibody, BNT327, across multiple solid tumor types.

Financial Performance

Cobenfy TRx increased +16.2% WoW, normalizing following the holiday week, reaching 1,933 TRx.

Product Development

BNT327 demonstrated promising median and 12-month landmark OS signals relative to benchmark studies, along with low treatment discontinuation rates due to AEs.

Negative Factors

Clinical Risk

The deal carries clinical risk of achieving clinically meaningful overall survival benefit.

Market Competition

The development space is crowded, including several PD-L1 and PD-1 VEGF bispecifics in development.

Revenue Estimates

Cobenfy scripts are tracking behind what is needed to beat Visible Alpha consensus estimates for 2Q25 revenue.

Bristol-Myers Squibb Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb (BMY) is a global biopharmaceutical company headquartered in New York City. It is dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company focuses on therapeutic areas such as oncology, cardiovascular, immunoscience, and fibrosis. Key products include Opdivo and Yervoy in oncology, Eliquis for cardiovascular conditions, and Orencia for immunoscience.

How the Company Makes Money

Bristol-Myers Squibb generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the development, marketing, and distribution of prescription medicines that address areas with significant unmet medical needs. Key revenue streams include its blockbuster drugs in oncology, such as Opdivo and Yervoy, which are used in cancer treatment, and Eliquis, a leading anticoagulant. Additionally, the company invests heavily in research and development to expand its pipeline of potential new medicines. Partnerships and collaborations with other pharmaceutical companies and research institutions also play a significant role in BMY's revenue generation, enhancing its capabilities in drug discovery and commercialization. Furthermore, strategic acquisitions and alliances help Bristol-Myers Squibb maintain a competitive edge in the biopharmaceutical industry.

Bristol-Myers Squibb Financial Statement Overview

Summary

Bristol-Myers Squibb demonstrates resilient financial performance with strengths in cash flow generation and gross profitability. However, net income variability and increased leverage pose potential risks. Continued focus on stabilizing earnings and managing liabilities will be crucial for sustained financial health.

Income Statement

The income statement reveals a stable performance with gross profit margins consistently strong around 70%. However, the net profit margin has fluctuated significantly, with a notable loss in 2024. Revenue growth has been stable, with a slight decline in recent periods. The EBIT and EBITDA margins are solid for the TTM, reflecting efficient cost management despite earlier fluctuations.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. The equity ratio has decreased over time, suggesting an increase in liabilities relative to assets. Return on equity has varied, impacted by fluctuating net income, with a recent improvement in profitability contributing positively.

Cash Flow

Cash flow analysis is favorable, with strong and improving free cash flow, highlighting efficient cash generation. The operating cash flow to net income ratio indicates robust cash conversion efficiency, although historical net income volatility presents some risk. Free cash flow growth is positive, supporting a strong cash position.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
47.64B	48.30B	45.01B	46.16B	46.38B	42.52B
	Gross Profit
31.43B	34.33B	34.31B	36.02B	36.45B	30.75B
	EBIT
8.79B	5.89B	17.24B	10.33B	10.16B	5.13B
	EBITDA
16.18B	3.22B	19.42B	19.23B	20.19B	5.04B
	Net Income Common Stockholders
5.42B	-8.95B	8.03B	6.33B	6.99B	-8.99B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.78B	10.86B	12.28B	9.12B	13.98B	14.55B
	Total Assets
92.43B	92.60B	95.16B	96.82B	109.31B	118.48B
	Total Debt
51.24B	51.20B	41.46B	40.72B	45.60B	51.67B
	Net Debt
40.36B	40.85B	30.00B	31.59B	31.62B	37.13B
	Total Liabilities
74.98B	76.22B	65.67B	65.70B	73.31B	80.60B
	Stockholders Equity
17.39B	16.34B	29.43B	31.06B	35.95B	37.82B
Cash Flow		Free Cash Flow
13.09B	13.94B	12.65B	11.95B	15.23B	13.30B
	Operating Cash Flow
14.31B	15.19B	13.86B	13.07B	16.21B	14.05B
	Investing Cash Flow
-2.23B	-21.35B	-2.29B	-1.06B	-538.00M	-10.86B
	Financing Cash Flow
-10.51B	5.13B	-9.42B	-16.96B	-16.22B	-1.15B

Bristol-Myers Squibb Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Negative. The current price of 46.84 is below the 20-day moving average (MA) of 48.21, below the 50-day MA of 48.46, and below the 200-day MA of 53.40, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 40.78 is Neutral, neither overbought nor oversold. The STOCH value of 7.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMY.

Bristol-Myers Squibb Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	76 Outperform	$199.10B	11.54	39.31%	4.09%	4.40%	654.93%
GILD	71 Outperform	$134.34B	22.71	32.51%	2.92%	4.63%	1144.01%
PFE	70 Neutral	$135.77B	17.31	8.62%	7.20%	13.38%	―
SNY	67 Neutral	$116.28B	19.82	7.34%	4.64%	-4.57%	2.96%
BMY	63 Neutral	$95.32B	17.59	31.99%	6.28%	4.62%	―
GSK	63 Neutral	$79.12B	19.82	22.26%	4.44%	4.17%	-29.96%
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%

Bristol-Myers Squibb Corporate Events

Bristol-Myers Squibb Holds Annual Shareholder Meeting 2025

On May 6, 2025, Bristol-Myers Squibb held its Annual Meeting, where shareholders elected 11 directors to serve until the 2026 meeting. Key decisions included the approval of executive compensation and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025. However, shareholder proposals on Corporate Financial Sustainability and ceasing DEI efforts were not approved.

Bristol-Myers Squibb Q1 2025 Financial Results Announced

On April 24, 2025, Bristol Myers Squibb announced its financial results for the first quarter of 2025, reporting total revenues of $11.2 billion, a decrease of 6% compared to the previous year. Despite the decline in total revenues, the company’s Growth Portfolio showed significant progress with a 16% increase in revenues, driven by strong performances from products like Opdivo, Breyanzi, Reblozyl, and Camzyos. The company raised its 2025 revenue guidance to a range of $45.8 billion to $46.8 billion, reflecting confidence in its strategic initiatives and pipeline progress.